检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:付卫江[1] 杨秋安[1] 潘振华[1] 刘恩宇[2] 高爽[3] 韩文斐[1] 付雷[1] 闵瑞[1]
机构地区:[1]山东大学齐鲁医院肿瘤中心,山东济南250012 [2]山东大学齐鲁医院普外科,山东济南250012 [3]济南市第一人民医院急诊科,山东济南250011
出 处:《中国现代普通外科进展》2008年第3期216-219,共4页Chinese Journal of Current Advances in General Surgery
摘 要:目的:评价三维适形放射疗法同时替加氟联合顺铂化学疗法治疗局部晚期胰腺癌的疗效及毒性。方法:采用同时放化学疗法治疗局部晚期胰腺癌患者19例,放射治疗采用三维适形放射治疗,常规分割,共54~62Gy;化学治疗第1~5天,替加氟800mg/d、顺铂20mg/d,21d为1个周期,共4个周期;化学治疗与放射治疗同时在第1天开始。结果:治疗总有效率36.8%;治疗前后CA199均数分别为425kU/L和79kU/L,差异有统计学意义;中位生存时间为10.9个月,1年生存率42.1%,2年生存率21.1%。结论:三维适形放射疗法同时替加氟联合顺铂化学疗法治疗局部晚期胰腺癌疗效与健择等其他同步化学治疗方案疗效相似,毒副反应患者能够耐受,值得进一步研究。Objective: To evaluate the effect and toxicity of concurrent chemo-radiotherapy consisting of three dimensional-conformal radiotherapy and cisplatin (CDDP)/tegafur(FT-207) infusion in patients with locally advanced pancreatic cancer. Methods; Nineteen patients with locally advanced pancreatic cancer were treated with concurrent chemoradiotherapy. Three dimension al-conformal radiotherapy of 54-62Gy was delivered at the rate of 1.8-2Gy per fraction. Concurrentchemoradiotherapy was given at the first day (Chemotherapy: FT-207 800mg/d and CDDP 20mg/d, 1-5 of 21-day cycle, at least four cycles.) The t-test was performed to compare the level of CA-199 before and after therapy. Overall survival rate was estimated by the Kaplan-Meier method. Results: The overall response rate was 36.8%. The level of CA-199 was 425u/ml before therapy and 79u/ml after therapy (P〈0.02). The median survival time was 10.9 months. The 1-year survival rate was 42.1% and 2-year survival rate was 21.1 %. Conelusion: Three dimensional-conformal radiotherapy combined with FT-207 and CDDP chemotherapy had similar effect with concurrent gemcitabine (GEM) chemotherapy for the treatment of patients with locally advanced pancreatic cancer.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.116.80.77